Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNC1
Period2020-01-01 → 2020-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100L1LQ.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥314m2020-01-01 → 2020-12-31StandaloneNet sales
Revenue¥1.3bn2019-01-01 → 2019-12-31StandaloneNet sales
Revenue¥169m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Revenue¥229m2017-01-01 → 2017-12-31dStandaloneNet sales (5-year summary)
Revenue¥178m2016-01-01 → 2016-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.7bn2020-01-01 → 2020-12-31StandaloneOperating income
Operating income−¥511m2019-01-01 → 2019-12-31StandaloneOperating income
Ordinary income−¥1.7bn2020-01-01 → 2020-12-31StandaloneOrdinary income
Ordinary income−¥539m2019-01-01 → 2019-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥864m2016-01-01 → 2016-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥2.1bn2020-01-01 → 2020-12-31StandaloneIncome before income taxes
Profit before tax−¥909m2019-01-01 → 2019-12-31StandaloneIncome before income taxes
Net income−¥2.1bn2020-01-01 → 2020-12-31StandaloneProfit loss
Net income−¥912m2019-01-01 → 2019-12-31StandaloneProfit loss
Net income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet income loss (5-year summary)
Net income−¥931m2016-01-01 → 2016-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.8bnat 2020-12-31StandaloneAssets
Total assets¥4.4bnat 2019-12-31StandaloneAssets
Total assets¥3.4bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.5bnat 2017-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.1bnat 2016-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥793mat 2020-12-31StandaloneLiabilities
Total liabilities¥926mat 2019-12-31StandaloneLiabilities
Net assets / equity¥2.0bnat 2020-12-31StandaloneNet assets
Net assets / equity¥3.5bnat 2019-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2018-12-31dStandaloneNet assets
Net assets / equity¥2.9bnat 2017-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.6bnat 2016-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.1bnat 2020-12-31StandaloneCash and deposits
Cash and deposits¥3.3bnat 2019-12-31StandaloneCash and deposits
Cash & equivalents¥1.8bnat 2020-12-31StandaloneCash and cash equivalents
Cash & equivalents¥3.1bnat 2019-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2018-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.9bnat 2017-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.4bnat 2016-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥238m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥903m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥38m2020-01-01 → 2020-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥4m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥342m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥132m2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥257m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥242m2020-01-01 → 2020-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2019-01-01 → 2019-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥6m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-145.582020-01-01 → 2020-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-65.552019-01-01 → 2019-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-104.552018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥136.43at 2020-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥240.71at 2019-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥216.61at 2018-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥263.54at 2017-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio71.4%at 2020-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.7%at 2019-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.3%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.9%at 2017-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued14,641,900at 2020-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued14,331,300at 2019-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued13,346,000at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,086,000at 2017-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees32at 2020-12-31StandaloneNumber of employees
Employees27at 2019-12-31StandaloneNumber of employees
Employees30at 2018-12-31dStandaloneNumber of employees
Employees29at 2017-12-31dStandaloneNumber of employees
Employees30at 2016-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 43
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2020-01-01 → 2020-12-31¥3m
Reconciling Itemsreconcilingdepreciation2020-01-01 → 2020-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2020-12-31¥2.7bn
Reconciling Itemsreconcilingsegment profit2020-01-01 → 2020-12-31−¥888m
Diagnostic Divisionreportable segmentcapex2020-01-01 → 2020-12-31¥14m
Diagnostic Divisionreportable segmentdepreciation2020-01-01 → 2020-12-31¥2m
Diagnostic Divisionreportable segmentemployeesat 2020-12-312 pure
Diagnostic Divisionreportable segmentrevenue2020-01-01 → 2020-12-31¥610,000
Diagnostic Divisionreportable segmentrevenue external2020-01-01 → 2020-12-31¥610,000
Diagnostic Divisionreportable segmentsegment assetsat 2020-12-31¥22m
Diagnostic Divisionreportable segmentsegment profit2020-01-01 → 2020-12-31−¥73m
Pharmaceutical Divisionreportable segmentemployeesat 2020-12-3112 pure
Pharmaceutical Divisionreportable segmentrevenue2020-01-01 → 2020-12-31¥314m
Pharmaceutical Divisionreportable segmentrevenue external2020-01-01 → 2020-12-31¥314m
Pharmaceutical Divisionreportable segmentsegment assetsat 2020-12-31¥91m
Pharmaceutical Divisionreportable segmentsegment profit2020-01-01 → 2020-12-31−¥713m
—segment totalemployeesat 2020-12-3114 pure
Total Of Reportable Segments And Otherssegment totalcapex2020-01-01 → 2020-12-31¥14m
Total Of Reportable Segments And Otherssegment totaldepreciation2020-01-01 → 2020-12-31¥2m
Total Of Reportable Segments And Otherssegment totalrevenue2020-01-01 → 2020-12-31¥314m
Total Of Reportable Segments And Otherssegment totalrevenue external2020-01-01 → 2020-12-31¥314m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2020-12-31¥113m
Total Of Reportable Segments And Otherssegment totalsegment profit2020-01-01 → 2020-12-31−¥787m
Reconciling Itemsreconcilingcapex2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingdepreciation2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2019-12-31¥3.9bn
Reconciling Itemsreconcilingsegment profit2019-01-01 → 2019-12-31−¥733m
Diagnostic Divisionreportable segmentcapex2019-01-01 → 2019-12-31¥10m
Diagnostic Divisionreportable segmentdepreciation2019-01-01 → 2019-12-31¥303,000
Diagnostic Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentsegment assetsat 2019-12-31¥10m
Diagnostic Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31−¥152m
Pharmaceutical Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentsegment assetsat 2019-12-31¥420m
Pharmaceutical Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31¥373m
Total Of Reportable Segments And Otherssegment totalcapex2019-01-01 → 2019-12-31¥10m
Total Of Reportable Segments And Otherssegment totaldepreciation2019-01-01 → 2019-12-31¥303,000
Total Of Reportable Segments And Otherssegment totalrevenue2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2019-12-31¥430m
Total Of Reportable Segments And Otherssegment totalsegment profit2019-01-01 → 2019-12-31¥221m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 952
ItemContextValueUnit
Purchase of property plant and equipment inv cfPrior1YearDuration_NonConsolidatedMember-3290000JPY
Purchase of property plant and equipment inv cfCurrentYearDuration_NonConsolidatedMember-2700000JPY
Purchase of intangible assets inv cfPrior1YearDuration_NonConsolidatedMember-1000000JPY
Purchase of intangible assets inv cfCurrentYearDuration_NonConsolidatedMember－JPY
Payments for investments in capital of subsidiaries and affiliates inv cfPrior1YearDuration_NonConsolidatedMember－JPY
Payments for investments in capital of subsidiaries and affiliates inv cfCurrentYearDuration_NonConsolidatedMember-10763000JPY
Payments of long term loans receivable inv cfPrior1YearDuration_NonConsolidatedMember－JPY
Payments of long term loans receivable inv cfCurrentYearDuration_NonConsolidatedMember-21762000JPY
Payments for lease and guarantee deposits inv cfPrior1YearDuration_NonConsolidatedMember-146000JPY
Payments for lease and guarantee deposits inv cfCurrentYearDuration_NonConsolidatedMember-2346000JPY
Net cash provided by used in investment activitiesPrior1YearDuration_NonConsolidatedMember-4442000JPY
Net cash provided by used in investment activitiesCurrentYearDuration_NonConsolidatedMember-37577000JPY
Proceeds from long term loans payable fin cfPrior1YearDuration_NonConsolidatedMember200000000JPY
Proceeds from long term loans payable fin cfCurrentYearDuration_NonConsolidatedMember100000000JPY
Repayment of long term loans payable fin cfPrior1YearDuration_NonConsolidatedMember-77784000JPY
Repayment of long term loans payable fin cfCurrentYearDuration_NonConsolidatedMember-100000000JPY
Repayments of lease obligations fin cfPrior1YearDuration_NonConsolidatedMember-5795000JPY
Repayments of lease obligations fin cfCurrentYearDuration_NonConsolidatedMember-3147000JPY
Proceeds from issuance of common stock fin cfPrior1YearDuration_NonConsolidatedMember1006892000JPY
Proceeds from issuance of common stock fin cfCurrentYearDuration_NonConsolidatedMember245505000JPY
Purchase of treasury stock fin cfPrior1YearDuration_NonConsolidatedMember－JPY
Purchase of treasury stock fin cfCurrentYearDuration_NonConsolidatedMember-95000JPY
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember1123312000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember242261000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-1201000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember-14147000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember879440000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember-1274664000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember2218074000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember3097514000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember3097514000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember1822850000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember155158000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember348523000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember165885000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember242284000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember562694000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember987242000JPY
Business consignment expenses sgaPrior1YearDuration_NonConsolidatedMember202837000JPY
Business consignment expenses sgaCurrentYearDuration_NonConsolidatedMember63736000JPY
Taxes and dues sgaPrior1YearDuration_NonConsolidatedMember76916000JPY
Taxes and dues sgaCurrentYearDuration_NonConsolidatedMember81221000JPY
License fee sgaPrior1YearDuration_NonConsolidatedMember362717000JPY
License fee sgaCurrentYearDuration_NonConsolidatedMember50610000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember562694000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember987242000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember1292363000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember11481000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember1303844000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2019-12-31pass rounding
balance sheet identitynon_consolidated 2020-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2018-12-31pass
statement vs summary · net assetsnon_consolidated 2019-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · operating cash flownon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · operating cash flownon_consolidated 2020-01-01/2020-12-31pass
statement vs summary · revenuenon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · revenuenon_consolidated 2020-01-01/2020-12-31pass
statement vs summary · total assetsnon_consolidated 2019-12-31pass
statement vs summary · total assetsnon_consolidated 2020-12-31pass